Latest Articles
-
Medtronic Earnings Preview: New Products And Emerging Markets In Focus
Medical device maker Medtronic Inc. (NYSE: MDT) is expected to release its first quarter fiscal 2015 results Tuesday, August 19. (Fiscal years end with April.) In the previous quarter, the company reported revenue growth of 3.3% year over year ...
-
Positive MiniMed Trial Results Could Boost Medtronic’s Diabetes Sales
Medtronic (NYSE: MDT) recently announced the results of the OpT2mise trial, which showed that its MiniMed insulin pumps achieve better results than multiple daily injections in controlling glucose levels for people suffering from type 2 diabetes ...
-
Medtronic’s $43 Billion Covidien Buyout Is More Than Just A Tax Saving Deal
Global medical device maker Medtronic (NYSE: MDT) has agreed to buy healthcare and medical supplies major Covidien (NYSE:COV) in a cash-and-stock deal valued at close to $43 billion. This implies a premium of about 30% to Covidien’s previou...
-
Medtronic Reports Modest Revenue Growth But Litigation Hurts Profits
Medtronic ‘s (NYSE: MDT) recently reported fourth quarter fiscal 2014 results reflected operational revenue growth of 3.3% year-over-year (y-o-y) to about $4.57 billion, driven by growing acceptance of new products and robust sales in emerg...
-
Medtronic Earnings Preview: Cost Cutting Efforts In Focus
Medical device maker Medtronic, Inc. (NYSE: MDT) reported year-over-year (y-o-y) operational sales growth of over 4% in the third quarter of fiscal 2014 to about $4.2 billion, driven by steady growth across all its divisions. Its largest divisio...
-
Medtronic’s Pacemaker Sales Likely To Get A Boost From Positive MINERVA Trial Results
Medtronic ‘s (NYSE: MDT) pacemakers equipped with advanced pacing features can significantly delay the development of persistent atrial fibrillation (AF, irregular heartbeat) in patients with bradycardia (slow heart rate), according to new ...
-
Medtronic Gets Relief In Edwards Patent Case, But Near-Term U.S. Outlook For CoreValve Looks Grim
Providing temporary relief to Medtronic (NYSE: MDT), a U.S. appeals court has postponed the preliminary injunction issued against the company in connection with its patent infringement court case with rival medical device maker Edwards Lifescienc...
-
Industry To Closely Follow Upcoming Results Of Medtronic’s Unsuccessful Renal Denervation Trial
Global medical device maker Medtronic (NYSE:MDT) will be revealing details of its unsuccessful renal denervation trial- Symplicity HTN-3 – on Saturday, March 29, at the American College of Cardiology (ACC) meeting in Washington DC. Medtroni...
-
Medtronic Facing 700 Lawsuits Over Its Infuse Bone Graft Product
Medical device maker Medtronic (NYSE:MDT) recently announced in its quarterly filing that about 700 lawsuits have been filed by patients against the company over its Infuse synthetic bone graft product, and more could be expected in the future. A...
-
New Products And Global Expansion To Drive Medtronic’s CRDM Sales
Cardiac Rhythm Disease Management (CRDM) is Medtronic ‘s (NYSE: MDT) largest division, contributing about 30% of its sales. This division primarily deals with pacemakers and defibrillators for the diagnosis, treatment, and management of he...
-
Medtronic Reports Balanced Growth Across Divisions While Profit Marginally Falls
Medtronic, Inc. ‘s (NYSE: MDT) recently reported third quarter fiscal 2014 results reflected operational revenue growth of over 4% year over year to about $4.2 billion, driven by steady growth across all its divisions. Its largest divisions...
-
Medtronic Earnings Preview: Moderate Sales Growth To Continue, Margins Likely To Remain Stable
Medical device maker Medtronic, Inc. (NYSE: MDT) reported year-over-year (y-o-y) operational sales growth of 3.3% in the second quarter of fiscal 2014 driven by strong sales of its new products. Its largest division, Cardiac Rhythm Disease Manag...
-
Medtronic’s CoreValve Gets Early FDA Approval; U.S. Sales Likely To Get A Boost
A couple of weeks back, Medtronic, Inc. (NYSE: MDT) got FDA approval for its transcatheter CoreValve system, which came three months earlier than expected. The FDA granted early approval because the Extreme Risk Study results for CoreValve were ...
-
Abbott Earnings Preview: Steady Growth Expected Despite Short Term Weakness In Nutritionals
Abbott Labs (NYSE:ABT) is scheduled to release its Q4 2013 earnings on Wednesday, January 22. In the previous quarter, the company reported a 4.3% year-over-year increase in operational sales as Diagnostics, Abbott’s second largest business...
-
Abbott Had A Transformational 2013, Here’s What To Expect in 2014
Abbott Labs (NYSE:ABT) started 2013 by spinning off its proprietary pharmaceutical business as Abbvie (NYSE:ABBV) on January 1, 2013. With the move, the company began a new life as a healthcare firm whose major offerings include nutritional, diag...
